Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

Robert W FrenckNicola P KleinNicholas KitchinAlejandra GurtmanJudith AbsalonStephen LockhartJohn L PerezEmmanuel B WalterShelly SendersRuth BaileyKena A SwansonHua MaXia XuKenneth KouryWarren V KalinaDavid CooperTimothy JenningsDonald M BrandonStephen J ThomasÖzlem TüreciDina B TresnanSusan MatherPhilip R DormitzerUğur ŞahinKathrin U JansenWilliam C Grubernull null

Published in: The New England journal of medicine (2021)

The BNT162b2 vaccine in 12-to-15-year-old recipients had a favorable safety profile, produced a greater immune response than in young adults, and was highly effective against Covid-19. (Funded by BioNTech and Pfizer; C4591001 ClinicalTrials.gov number, NCT04368728.).

Keyphrases

young adults
coronavirus disease
sars cov
immune response
physical activity
respiratory syndrome coronavirus
childhood cancer
inflammatory response